6533b830fe1ef96bd12966bc

RESEARCH PRODUCT

Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function

Christoph DüberSimon Johannes GairingLukas MüllerJens MittlerFabian StoehrRoman KloecknerAline Mähringer-kunzMichael B. PittonDaniel Pinto Dos SantosPeter R. GalleArndt WeinmannFelix HahnFriedrich Foerster

subject

Cancer Researchmedicine.medical_specialtybusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensalbumin-bilirubin gradehepatocellular carcinomatransarterial chemoembolizationprognostic nutritional indexmedicine.diseaseGastroenterologyConcordance indexCombined approachTumor ablationArticlerisk predictionOncologyInternal medicineHepatocellular carcinomamedicineOverall survivalIn patientLiver functionbusinessGrading (tumors)RC254-282

description

A combination of albumin-bilirubin (ALBI) grading and the Prognostic Nutritional Index (PNI) was identified recently as a highly predictive tool for patients with hepatocellular carcinoma (HCC) undergoing tumor ablation. The present study evaluated this combination in patients undergoing transarterial chemoembolization (TACE). Between 2010 and 2020, 280 treatment-naïve patients were retrospectively identified. The influence of ALBI grade, PNI and the novel ALBI-PNI on the median overall survival (OS) was assessed. In the next step, the prognostic ability of the combined approach was compared to established scoring systems. Both ALBI grade 2−3 and a low PNI were highly predictive for median OS (ALBI grade 1–3: 39.0 vs. 16.3 vs. 5.4 months, p &lt

yearjournalcountryeditionlanguage
2021-08-05Cancers
10.3390/cancers13163961http://dx.doi.org/10.3390/cancers13163961